Alcimed: Innovation and New Business Consulting

At the moment, our premium content

EcoXplorer: Explore your product’s environmental impact

Who is Alcimed?

Every day we help build the world of tomorrow

For over 30 years

Our team of 220 explorers has been supporting our clients across the world in their innovation and new market development projects.

Our exploration territories

"The benefit that really Alcimed brought to the table was to have an expert intermediary to take us through the process to really challenge our thinking."

Mark TWYMAN

Senior VP and Chief Commercial Officer
"The Alcimed team has allowed us to structure the project appropriately, to plan it in the best possible way, and to make sure that every single step of the project was successful."

Federico Bianco

Head of the Special Care Unit
"Together between Alcimed and Nestlé Health Science, we made informed decision on where the best opportunities were and why and how to select the most valuable assets in our investigation."

Bernard Cuenoud

Global Head of Research and Clinical Development

Strategic marketing

Clients & Patients

R&D

Commercial strategy

Innovation

New partners

Strategy

Healthcare

Environment & Climate

Beauty & Nutrition

Energy & mobility

Sovereignty

Tech & data

Healthcare

Sustainability in pharma R&D: water, pollution and circularity

Regulatory pressure accelerates sustainability in pharma R&D Regulatory signals are already shifting R&D timelines. The European Medicines Agency’s updated guidance on environmental risk ...
Cross-sector

Harnessing the digital exhaust in healthcare: how pharma and wearables are revolutionizing patient care

The rise of the digital exhaust Healthcare is entering a new era characterized by the constant stream of information generated by wearables and connected devices. From smartphones that count steps ...
Healthcare

Virtual reality: a real game-changer for neurological rehabilitation

The rising demand for innovation in neurological rehabilitation Limited functional recovery in many neurological indications Globally, an estimated 2.41 billion people could benefit from ...
Cross-sector

From selective consolidation to strategic reinvention: 3 drivers shaping MedTech M&A in 2026

The momentum from 2025 is carrying decisively into 2026. After a year defined by selective, high-value consolidation, the MedTech M&A will likely be shaped less by deal volume and more by ...
Healthcare

Health data: how to accelerate access and valorization in France in 2026?

Context and challenges of access to health data According to the French Data Protection Authority (CNIL), health data are personal data relating to the physical or mental health of a person, ...